3SBio (1530.HK) Stock Price
3SBio Price
Revenue has compounded at 29.6% per year over the past 19 years to 20.61 B CNY. Earnings per share have grown at 13.8% per year over the last 13 years. 3SBio's net margin stands at 47.9%, up from 25.9% several years earlier. 3SBio currently offers a dividend yield of about 2.09%. The payout ratio is around 5% of earnings. The dividend has grown at 20.3% per year over the past 7 years. Analysts set a median price target of 32.52 CNY, implying 171.6% above the current price. Of 18 analysts, 16 rate the stock a buy — an overall Buy consensus.
3SBio stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
3SBio business model & stock analysis
Frequently asked questions about 3SBio
3SBio Inc operates as a leading biotechnology company. The business model of 3SBio Inc revolves around the research, development, manufacturing, and commercialization of biopharmaceutical products. The company focuses on developing innovative therapies to address unmet medical needs, particularly in the fields of oncology, nephrology, and autoimmune diseases. By leveraging their expertise in biologics and in-house manufacturing capabilities, 3SBio Inc aims to deliver high-quality and affordable medicines to patients worldwide. With a commitment to advancing healthcare, 3SBio Inc continues to invest in R&D efforts and strategic partnerships, aiming to improve patient outcomes and enhance their market presence.
3SBio Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of 3SBio Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis International AG, Amgen Inc, and Roche Holding AG.
3SBio Inc is a leading biotechnology company specializing in the research, development, and manufacturing of innovative biopharmaceutical products. Founded in 1993, the company has a rich history in the biotech industry. With its headquarters in China, 3SBio Inc has expanded globally and gained recognition for its expertise in therapeutic areas including nephrology, oncology, and immunology. The company is committed to improving patient outcomes through the development of high-quality, life-saving medications. 3SBio Inc has established itself as a trusted name in the biopharmaceutical sector, delivering innovative solutions to address unmet medical needs and improve the quality of life for patients worldwide.
3SBio Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange in 2015, marking a major milestone in its history. Furthermore, 3SBio Inc has seen remarkable growth and success in the biopharmaceutical industry, particularly in the development and commercialization of innovative medicines. They have obtained regulatory approvals for various products, expanded their product portfolio, and established strategic partnerships to enhance their market presence. The company's dedication to research and development has also resulted in numerous scientific achievements and breakthroughs. Overall, 3SBio Inc has demonstrated consistent progress and remains a leading player in the biopharmaceutical sector.
3SBio Inc is primarily present in China and the United States.
3SBio Inc represents a commitment to innovation, integrity, and excellence in the biopharmaceutical industry. The company values putting patients first and developing high-quality therapeutic solutions. With a focus on research and development, 3SBio Inc is dedicated to discovering, developing, and commercializing innovative biopharmaceutical products. The company's corporate philosophy centers around offering effective and affordable treatments to improve patients' lives. By staying true to their core values, 3SBio Inc aims to make a positive impact on healthcare and contribute to the well-being of individuals worldwide.
Analysts currently set an average price target of 33.04 CNY for the 3SBio stock (median: 32.52 CNY), implying +176.0 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the 3SBio stock: 16 recommend buying, 2 holding and 0 selling. For 2026, analysts expect 3SBio to generate revenue of 9.56 B CNY and earnings per share of 0.96 CNY.
Converted at the current exchange rate, the 3SBio share trades at 1.60 EUR (11.97 CNY).
The 3SBio share (1530.HK) is listed on 5 stock exchanges, including: Hongkong (HKEX) (1530.HK), Frankfurt (83B.F), München (83B.MU), Düsseldorf (83B.DU).
The Chinese company 3SBio Inc is a leading company in the biopharmaceutical industry, specializing in the development, manufacturing, and marketing of biological drugs. 3SBio focuses on the areas of oncology, immunology, nephrology, and infectious diseases. The main products of 3SBio include biosimilars of innovative drugs such as rituximab, enoxaparin, adalimumab, darbepoetin alfa, pegaspargase, and etanercept. Biosimilars are biologically manufactured drugs that have similar active ingredients as original biologics and thus provide a more cost-effective alternative. 3SBio has the largest market share for biosimilars in China and continually expands its portfolio. In addition to biosimilars, 3SBio also offers innovative biological drugs. One example is Tpiao, a recombinant human thrombopoietin receptor agonist. It is used to treat thrombocytopenia in patients with hepatitis B or hepatitis C infections. Another important area for 3SBio is nephrology. The company has various products in its portfolio that are used to treat kidney diseases. These include, for example, the erythropoiesis-stimulating agent (ESA) ferumoxytol, which is used to treat iron deficiency anemia in chronic kidney disease, as well as binodenoson, an adenosine receptor agonist used for diagnostic imaging of kidney diseases. The business model of 3SBio Inc is based on the acquisition of promising technologies, its own research and development work, and the manufacturing and marketing of biological drugs. The company works closely with regulatory authorities and health organizations to achieve fast market approval for its products. An important aspect is also international distribution. 3SBio strategically enters growth markets in Asia, especially in China, and expands into other parts of the world. Through partnerships with other companies and the acquisition of firms in the biopharmaceutical industry, 3SBio continuously expands its value chain and its portfolio. Overall, 3SBio pursues a diversified business model based on the utilization of synergies in the areas of research, development, manufacturing, and marketing of biological drugs. By utilizing biosimilars and innovative active ingredients, the company has achieved high competitiveness and is on a path of expansion.
The expected revenue of 3SBio is 9.56 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of 3SBio is 2.38 B CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of 3SBio is currently 12.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the 3SBio stock.
The price-to-sales ratio (P/S) of 3SBio is currently 3.11. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the 3SBio stock.
The Eulerpool Quality Score for 3SBio is 8/10.
The ISIN of 3SBio is KYG8875G1029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of 3SBio is A14T7Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of 3SBio is 1530.HK. The ticker symbol is used to trade 3SBio shares on the stock exchange.
3SBio stock
All fundamentals and in-depth analysis of 3SBio
Our stock analysis for 3SBio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 3SBio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.